Virtus Investment Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Virtus Investment Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,867	Closed	-$109K	–	389
2023 Q4	$109K	Hold	20,867	–	–	0.08%	239
2023 Q3	$329K	Sell	20,867 -998	-5%	-$17.9K	0.22%	116
2023 Q2	$425K	Buy	21,865 +14,557	+199%	+$345K	0.29%	102
2023 Q1	$207K	Sell	7,308 -144	-2%	-$4.28K	0.15%	179
2022 Q4	$218K	Hold	7,452	–	–	0.15%	184
2022 Q3	$197K	Buy	+7,452	New	+$273K	0.09%	199

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Virtus Investment Advisers's EGRX Position: Q1 2024 in Review

Virtus Investment Advisers sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 20,867 shares — an estimated $109K sold.

Virtus Investment Advisers first reported a position in EGRX in Q3 2022 and held it in 6 quarters. The position peaked at $425K in Q2 2023. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

Virtus Investment Advisers reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Virtus Investment Advisers sold 20,867 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $109K.
Virtus Investment Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2022 and held it in 6 quarters.
Virtus Investment Advisers's Eagle Pharmaceuticals, Inc. position peaked at $425K in Q2 2023.
91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Virtus Investment Advisers's 13F filing for Q1 2024, filed 16 May 2024.